Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.

Yuqing Zhang, Courtney W Houchen, Min Li

Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Aug 02

filter terms:

The patient-derived organoids (PDO) platform recapitulates the phenotype, genotype, and molecular characteristics of primary tumors. High-throughput drug screening in terms of pharmacotyping using standard-of-care chemotherapy agents in the PDO platform has shown promising sensitivities to guide precision medicine for individual patients with pancreatic ductal adenocarcinoma (PDAC) within a clinically relevant time frame. See related article by Seppälä et al., p. 3296. ©2022 American Association for Cancer Research.

Citation

Yuqing Zhang, Courtney W Houchen, Min Li. Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Aug 02;28(15):3176-3178